Package leaflet: Information for the patient. Desloratadine Cipla 5 mg film-coated tablets. Desloratadine

Similar documents
PACKAGE LEAFLET Page 1 of 6

BIJSLUITER: INFORMATIE VOOR DE GEBRUIKER. Deslorasam 5 mg filmomhulde tabletten Desloratadine

Package leaflet: Information for the user. Desloratadine Archie Samuel 5 mg filmomhulde tabletten Desloratadine

B. PACKAGE LEAFLET 1

Package leaflet: Information for the patient

1. WHAT CO-AMOXICLAV TABLETS IS AND WHAT IT IS USED FOR

PACKAGE LEAFLET: INFORMATION FOR THE USER. AMOXICILLIN 250mg and 500mg CAPSULES BP Amoxicillin (as amoxicillin trihydrate)

Package leaflet: Information for the patient. Co-amoxiclav 250 mg/125 mg film-coated tablets Amoxicillin/clavulanic acid

2 What you need to know before you take Augmentin

PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for the user. Amlodipin Accord 10 mg tablets. Amlodipine

Package leaflet: Information for the patient. Co-amoxiclav 500 mg/125 mg film-coated tablets. amoxicillin/ clavulanic acid

Package leaflet: Information for the user

Package leaflet: Information for the patient. FLUCLOXACILLIN 250MG/5ML ORAL SOLUTION Flucloxacillin

Package leaflet: Information for the user. Amlodipin Aurobindo 10 mg tablets. Amlodipine

Package leaflet: Information for the user Augmentin 875 mg/125 mg film-coated tablets Amoxicillin/clavulanic acid

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICATION PATIENT MEDICATION INFORMATION. Moxifloxacin tablets (as moxifloxacin hydrochloride)

Amoxicillin 250mg Hard Capsules Amoxicillin 500mg Hard Capsules

AMLODIPINE 5 MG TABLETS AMLODIPINE 10 MG TABLETS Amlodipine

Amlodipin Bluefish 10 mg tablets. amlodipine

PATIENT INFORMATION LEAFLET DYNA CEFPODOXIME 100 mg / DYNA CEFPODOXIME SUSPENSION:

New Zealand Consumer Medicine Information

PATIENT INFORMATION LEAFLET

Package leaflet: Information for the patient. Amoxicilline/Clavulaanzuur Torrent 500 mg/125 mg filmomhulde tabletten. Amoxicillin Clavulanic acid

Package leaflet: Information for the patient. Germentin 500 mg/125 mg film coated tablets Amoxicillin/clavulanic acid

Package leaflet: Information for the user

AMLODIPINE GENERICHEALTH

B. PACKAGE LEAFLET 1

PACKAGE LEAFLET Page 1 of 7

PACKAGE LEAFLET: Information for the user. amlodipino cinfa 5 mg tablets

2. What you need to know before you take Doxycycline capsule

Package leaflet: Information for the user. GENTAMICIN VISION 3 mg/ml eye drops, solution Gentamicin

PACKAGE LEAFLET: INFORMATION FOR THE USER. Amlodipine 5 mg Tablets Amlodipine 10 mg Tablets (Amlodipine Besilate)

Moxifloxacin APOTEX Contains the active ingredient moxifloxacin (as hydrochloride monohydrate)

PACKAGE LEAFLET: INFORMATION FOR THE USER. Amikacin 250 mg/ml Injection

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

PACKAGE LEAFLET: INFORMATION FOR THE USER. GENTAMICIN VISION 3 mg/g eye ointment Gentamicin

OFLOXACIN TABLETS MEDICATION GUIDE

Amlodipine Pfizer 5 mg and 10 mg tablets Amlodipine

MEDICATION GUIDE FLOXIN [Flox in] (ofloxacin)

Package leaflet: information for the user

PATIENT INFORMATION LEAFLET GENTAMICIN 10MG/ML SOLUTION FOR INJECTION OR INFUSION. and GENTAMICIN 40MG/ML SOLUTION FOR INJECTION OR INFUSION

Blooms The Chemist Amlodipine / Atorvastatin

Package leaflet: Information for the patient Genticin 80mg/2ml Solution for Injection Gentamicin

SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the user. AUGMENTIN DUO 400 mg/57 mg/5 ml powder for oral suspension Amoxicillin/clavulanic acid

Package leaflet: Information for the user

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. (HYDROmorphone Hydrochloride) Sterile Solution for Injection

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS MUTUAL RECOGNITION PROCEDURE

Keep this leaflet with your medicine. You may want to read it again. What this medicine is used for

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

PACKAGE LEAFLET: INFORMATION FOR THE USER. Amlodipine maleate. Read all of this leaflet carefully before you start taking this medicine.

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE. PATIENT MEDICATION INFORMATION HYDROmorphone Hydrochloride Injection USP

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE. PATIENT MEDICATION INFORMATION N HYDROmorphone HP 10

Package leaflet: Information for the user. Moxifloxacin 400 mg film-coated tablets. Adults Active substance: Moxifloxacin

NL/H/882/ / Amlodipine CT 5 mg, tabletten Amlodipine CT 10 mg, tabletten

Minims Chloramphenicol

For a copy of a large print leaflet, Ph: Read this leaflet carefully before taking your medicine.

FDA-Approved Medication Guide MEDICATION GUIDE Moxifloxacin Hydrochloride Tablets (mox'' i flox' a sin hye'' droe klor' ide) Rx only

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

LABELLING AND PACKAGE LEAFLET

NL/H/880/01-02 FINAL PL

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

DBL Doxycycline Doxycycline Hydrochloride (dox-i-sye-kleen)

Prescription Label. Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long):

Metacam is an anti-inflammatory medicine used in cattle, pigs, horses, dogs, cats and guinea pigs.

PACKAGE LEAFLET: INFORMATION FOR THE USER. Amlodipine 10 mg Tablets. (Amlodipine Besilate)

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Antibiotics. Information for patients and carers Pharmacy Department. Patient information leaflet

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the patient. Flomocin 400mg film-coated tablets Moxifloxacin

Vetoquinol/DOLPAC Small dogs/european Renewal June 2011 SUMMARY OF PRODUCT CHARACTERISTICS

Prescription Label. Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long):

B. PACKAGE LEAFLET 1

Package leaflet: Information for the user. HYDROCORTISON CUM CHLORAMPHENICOL 5 mg/g + 2 mg/g eye ointment hydrocortisone acetate, chloramphenicol

[09/2018] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Prescription Label. Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long):

SUMMARY OF PRODUCT CHARACTERISTICS. KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats

uk-pl-nl0979v026-clean.doc Page 1 of 9

SUMMARY OF PRODUCT CHARACTERISTICS

Veterinary Medicinal Product

SUMMARY OF PRODUCT CHARACTERISTICS. Milprazon 16 mg/40 mg film-coated tablets for cats weighing at least 2 kg

Prescription Label. Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long):

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

TO ENSURE ADEQUATE ABSORPTION, ALWAYS ADMINISTER PROGRAM FLAVOR TABS IN CONJUNCTION WITH A NORMAL MEAL.

Therios 300 mg and 750 mg Palatable Tablets for Dogs

Prescription Label. Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long):

Summary of Product Characteristics

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS MUTUAL RECOGNITION PROCEDURE

Oral and intestinal candidiasis. As adjuvant treatment with other local nystatin preparations to prevent reinfection.

Veterinary Medicinal Product

SUMMARY OF PRODUCT CHARACTERISTICS 1.B.1 SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Transcription:

Package leaflet: Information for the patient Desloratadine Cipla 5 mg film-coated tablets Desloratadine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Desloratadine Cipla is and what it is used for 2. What you need to know before you take Desloratadine Cipla 3. How to take Desloratadine Cipla 4. Possible side effects 5. How to store Desloratadine Cipla 6. Contents of the pack and other information 1. What Desloratadine Cipla is and what it is used for What Desloratadine Cipla is Desloratadine Cipla contains desloratadine which is an antihistamine. How Desloratadine Cipla works Desloratadine Cipla is an anti-allergy medicine that does not make you drowsy. It helps control your allergic reaction and its symptoms. When Desloratadine Cipla should be used Desloratadine relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older. These symptoms include sneezing, runny or itchy nose, itchy palate, and itchy, red or watery eyes. Desloratadine Cipla is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy). These symptoms include itching and hives. Relief of these symptoms lasts a full day and helps you to resume your normal daily activities and sleep.

2. What you need to know before you take Desloratadine Cipla Do not take Desloratadine Cipla if you are allergic to desloratadine, or any of the other ingredients of this medicine (listed in section 6) or to loratadine. Warnings and precautions Talk to your doctor or pharmacist before taking Desloratadine Cipla if you have poor kidney function. if you have medical or familial history of seizures. Use in children and adolescents Do not give this medicine to children less than 12 years of age. Other medicines and Desloratadine Cipla Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. There are no known interactions of Desloratadine Cipla with other medicines. Desloratadine Cipla with food and drink Desloratadine Cipla may be taken with or without a meal. Use caution when taking Desloratadine Cipla with alcohol. Pregnancy,breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Taking Desloratadine Cipla is not recommended if you are pregnant or nursing a baby. Fertility There is no data available on male/female fertility. Driving and using machines At the recommended dose, this medicine is not expected to affect your ability to drive or use machines. Although most people do not experience drowsiness, it is recommended not to engage in activities requiring mental alertness, such as driving a car or operating machinery until you have established your own response to the medicinal product. 3. How to take Desloratadine Cipla Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Adults and adolescents 12 years of age and over The recommended dose is one tablet once a day with water, with or without food. This medicine is for oral use.

Swallow the tablet whole. Regarding the duration of treatment, your doctor will determine the type of allergic rhinitis you are suffering from and will determine for how long you should take Desloratadine Cipla. If your allergic rhinitis is intermittent (presence of symptoms for less than 4 days per week or for less than 4 weeks), your doctor will recommend you a treatment schedule that will depend on the evaluation of the history of your disease. If your allergic rhinitis is persistent (presence of symptoms for 4 days or more per week and for more than 4 weeks), your doctor may recommend you a longer term treatment. For urticaria, the duration of treatment may be variable from patient to patient and therefore you should follow the instructions of your doctor. If you take more Desloratadine Cipla than you should Take this medicine only as it is prescribed for you. No serious problems are expected with accidental overdose. However, if you take more Desloratadine Cipla than you were told to, tell your doctor or pharmacist immediately. If you forget to take Desloratadine Cipla If you forget to take your dose on time, take it as soon as possible and then go back to your regular dosing schedule. Do not take a double dose to make up for a forgotten dose. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. During the marketing of Desloratadine Cipla, cases of severe allergic reactions (difficulty in breathing, wheezing, itching, hives and swelling) have been reported very rarely. If you notice any of these serious side effects, stop taking the medicine and seek urgent medical advice straight away. In clinical studies in adults, side effects were about the same as with a dummy tablet. However, fatigue, dry mouth and headache were reported more often than with a dummy tablet. In adolescents, headache was the most commonly reported side effect. In clinical studies with desloratadine, the following side effects were reported as: Common (may affect up to 1 in 10 people) fatigue dry mouth headache Adults During the marketing of this medicine, the following side effects were reported as:

Very rare: (may affect up to 1 in 10,000 people) severe allergic reactions rash pounding or irregular heartbeat fast heartbeat stomach ache feeling sick (nausea) vomiting upset stomach diarrhoea dizziness drowsiness inability to sleep muscle pain hallucinations seizures restlessness with increased body movement liver inflammation abnormal liver function tests Not known (frequency cannot be estimated from the available data) unusual weakness yellowing of the skin and/or eyes increased sensitivity of the skin to the sun, even in case of hazy sun, and to UV light, for instance to UV lights of a solarium change in the way the heart beats abnormal behavior aggression weight increased, increased appetite Children Not known (frequency cannot be estimated from the available data) slow heartbeat change in the way the heart beats abnormal behavior aggression Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine. 5. How to store Desloratadine Cipla Keep this medicine out of the sight and reach of children. Store below 25 0 C.

Store in the original package in order to protect from light. Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment. 6. Contents of the pack and other information What Desloratadine Cipla contains The active substance is desloratadine. Each film-coated tablet contains 5 mg desloratadine. The other ingredients are: - Tablet core: mannitol, low-substituted hydroxyl propyl cellulose, castor oil hydrogenated, silica colloidal anhydrous, talc, simethicone. - Tablet coating: hypromellose, titanium dioxide (E171), macrogol, indigo carmine aluminium lake (E132) What Desloratadine Cipla looks like and contents of the pack Desloratadine Cipla are light blue coloured, circular, biconvex, film-coated tablet with diameter of 7.00 mm plain on both sides. Carton containing blister (PVC/ACLAR film and plain aluminium foil) of 5, 10, 20, 30, 50 and 100 tablets each. Not all pack sizes may be marketed. Marketing authorization holder [To be completed nationally] Manufacturer S & D Pharma, CZ, spol. s.r.o. Registered office of the company: Písnická 22/546, 142 00 Prague 4, Czech Republic, IČ: 25087193 Place of manufacture: Theodor 28, 273 08 Pchery (PHARMOS a.s. facility), Czech Republic Cipla (EU) Limited, Dixcart House, Addlestone Road, Bourne Business Park, Addlestone, Surrey, KT15 2LE, United Kingdom Cipla Europe NV De Keyserlei 58-60, Box-19, 2018 Antwerp, Belgium

This medicinal product is authorised in the Member States of the EEA under the following names Sweden - Desloratadine Cipla 5 mg filmdragerade tabletter Czech Republic DELESIT 5 mg potahované tablety Slovak Republic DELESIT 5 mg filmom obalené tablety Denmark- Desloratadin Cipla Spain- Desloratadine Cipla 5 mg comprimidos recubiertos con película Romania- Desloratadina Amring 5 mg comprimate filmate United Kingdom- Desloratadine 5 mg film-coated tablets This leaflet was last revised in 04/2018